Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Radiopharm Theranostics - Application for quotation of securities (ASX:RAD)

To view the application for quotation of securities, download the attached PDF.

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

HIGHLIGHTS: Pivalate achieves positive Phase 2a data in brain mets trial Joint venture with MD Anderson to develop novel pharmaceuticals FDA grants orphan drug status and rare ...read more

Radiopharm Theranostics - RAD agreement with NorthStar for supply of Actinium-225 (ASX:RAD)

Sydney, Australia and Beloit, Wisconsin, U.S. – October 26, 2022 -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both ...read more

Radiopharm Theranostics - Reinstatement to Quotation (ASX:RAD)

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding the compl...read more

Radiopharm Theranostics - Supplementary Prospectus (ASX:RAD)

To view the supplementary prospectus, download the attached PDF.

Radiopharm Theranostics - Successful Completion of Institutional Entitlement Offer (ASX:RAD)

Successful completion of the institutional component of the accelerated non-renounceable entitlement offer originally announced on 19 October 2022, raising approximately $5.5...read more

Update - Proposed issue of securities - RAD (ASX:RAD)

To view the Proposed issue of securities, download the attached PDF.

Radiopharm Theranostics - Entitlement Offer - Presentation (ASX:RAD)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Entitlement Offer to raise up to $10 million (ASX:RAD)

-- Radiopharm is undertaking a 1 for 3.55 accelerated non-renounceable entitlement offer to raise up to $10 million (before costs) at A$0.14 per New Share -- Provides the Company with runway until ...read more

Radiopharm Theranostics - Prospectus (ASX:RAD)

Accelerated non-renounceable pro rata entitlement offer of 1 New Share for every 3.55 Existing Shares (and 1 New Option for every New Share issued) at an Offer Price of $0.14 to raise up to approxim...read more

Proposed issue of securities - RAD (ASX:RAD)

To view the Proposed issue of securities, download the attached PDF.

Radiopharm Theranostics - Presentation - Pivalate achieves positive Phase 2 data (ASX:RAD)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Pivalate achieves positive Phase 2 data in brain mets trial (ASX:RAD)

-- F-18 Pivalate PET shows high uptake regardless of origin of primary tumour -- F-18 Pivalate can be used to monitor cerebral metastases -- Patients without previous external beam radiation show ...read more

Radiopharm Theranostics - Suspension from Official Quotation (ASX:RAD)

The securities of Radiopharm Theranostics Limited (‘RAD’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAD, pending the release of an announcem...read more

Radiopharm Theranostics - Notice of Annual General Meeting/Proxy Form (ASX:RAD)

To view the notice, download the attached PDF.

Viewing: 61 - 75 of 200 Previous | Next